Newsletter Signup | Join Community
Impotence, a common complication of prostate surgery may be reversible with minimally invasive end to end nerve grafting
New study suggest that commonly used androgen deprivation therapy treatment for prostate cancer increases dementia risk.
Men with prostate cancer have genomic defects that can be targeted with Lynparza and should undergo genomic testing.
Xtandi® + Zytiga® does not improve survival in advanced prostate cancer compared to Xtandi alone.
Erleada prolongs survival in non-metastatic Castration-resistant Prostate Cancer and for those with metastatic disease.
Initial results of KEYNOTE 365 study of Keytruda immunotherapy in prostate cancer released at 2019 ASCO
Xtandi® superior to non-steroidal anti-androgens and improves survival in all phases of advanced prostate cancer.
Urologists are one of the experts that treat prostate cancer with surgery or prostatectomy. How do you choose one?
Oncotype DX - Prostate The Beginning of Individualized Treatment
Studies demonstrate that Zytiga improves outcomes in men with newly diagnosed and ADT resistant prostate cancer.
UCLA Doctors Report that Five Days Sterotactic Radiation Therapy as Effective as 45 Days
Taxotere ineffective when used to treat early stage androgen sensitive prostate cancer.
Stay Current With Prostate Cancer Treatment Advances & Connect with Others
A new treatment, 177Lu-PSMA-617, targets radiation directly to prostate cancer
Xofigo (Radium 223) Treatment of Bone Metastases in Advanced Prostate and other cancers.
Understand the administration, side effects and answers to frequently asked questions about Xtandi® (Enzalutamide)
Keep current with advances in the early detection and treatment of Prostate Cancer
Dr. Mulhall M.D. of Memorial Sloan-Kettering Cancer Center discusses prostate cancer treatment and sexual function
Dr. Neal Shore: Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment
Taxotere® plus Emcyt® Confirmed Superior to Taxotere Alone for Hormone Refractory Prostate Cancer
In-depth interview with cartoonist Tom Batiuk and a look at his award winning cancer cartoon, Lisa’s Story.
Cancer Connect - Treatment of Stage IV (D) Prostate Cancer
Charles McFarland shares his experience with High Intensity Focused Ultrasound treatment of prostate cancer.
Did you know Arnold Palmer had prostate cancer? The golfing legend discussed his battle with prostate cancer.
Dr Cary Robertson of Duke University Explains Who is a Candidate for HIFU Treatment for Prostate Cancer
The Gleason grade and score are one of the major components communicated in a prostate biopsy pathology report and help
A second opinion should be considered by most patients diagnosed with prostate cancer.
Cancer Connect - Treatment for Recurring Prostate Cancer
Cancer Connect - Treatment of Stage III (C) Prostate Cancer
Cancer Connect - Treatment of Stage II Prostate Cancer
Treatment of Stage I Prostate Cancer
Understand the administration, side effects and answers to frequently asked questions about Erleada® (Apalutamide)
Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer
Myriad’s myRisk® Hereditary Cancer Finds More Than 12% of Men with Prostate Cancer Carry an Inherited Genetic Mutation
Two Advances in Prostate Cancer You Might Not Know About
Analysis Shows an Overall Survival Benefit with Provenge® in African American Men with Metastatic Prostate Cancer
Unique Gene Signature Predicts Potentially Lethal Prostate Cancers
Different Treatment Options Appear Equally Effective in Early Prostate Cancer
New Tool Helps Men Evaluate Watchful Waiting in Early Stage Prostate Cancer
Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer
FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer.
Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer.
Shorter, Intensive Radiation Can Be Recommended in Early Prostate Cancer.
Shorter Radiation Schedule Effective in Low-Risk Prostate Cancer.
Behavioral Therapy Reduces Incontinence after Prostatectomy.
Survival Improved In Advanced Prostate Cancer With Early Treatment With Chemotherapy Plus Hormonal Therapy.
Men Younger Than Age 60 May Have More Aggressive Prostate Cancer
Shorter Course of Radiation as Effective as Longer Course in Low-Risk Prostate Cancer
Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy
Medicare Initiates Coverage for Genomic Health’s Oncotype DX® Prostate Cancer Test Effective Immediately
Oncotype DX Increases Use of Active Surveillance in Prostate Cancer Patients
Prostvac® Vaccine Promising in Treatment of Metastatic Castration-Resistant Prostate Cancer
Researchers Develop New Potential Drug for Rare Leukemia; Separate Study Suggests Possible Role in Prostate Cancer
Radiation Plus Androgen-Deprivation Therapy Prolongs Survival for Older Men With Prostate Cancer
New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, Inspires “Your Prostate Your Decision”
American Society of Clinical Oncology Endorses AUA/ASTRO Guidelines on the Use of Radiation Treatment After Prostatectom
Radiation Therapy Benefits Selected Patients With Node-Positive Prostate Cancer
Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with Prostate Cancer.
Cabozantinib Development in Prostate Cancer Halted.
Advaxis and Merck Form Collaboration to Evaluate of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer.
New MD Anderson Research Questions Early Prostate Cancer Treatment Options.
Chemotherapy After Prostatectomy Delays Cancer Progression in High-Risk Prostate Cancers.
Genomic Health Demonstrates the Importance of Utilizing Multiple Pathways to Predict Behavior in Prostate Cancers
Recent Studies Find Oncotype DX® Can Reliably Predict Risk of Aggressive Prostate Cancer
Radical Prostatectomy Offers Long-Term Benefit Over Watchful Waiting in Early Prostate Cancer
Longest Follow-Up to Date Shows Active Surveillance is Safe and Feasible
Radical Prostatectomy Shows Significant Long-Term Benefit in Early Prostate Cancer
High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer
Oncotype DX Prostate Cancer Test Is Reliable Even in Small Samples
Long-Term Hormone Therapy Offers No Benefit in Intermediate-Risk Prostate Cancer
Metformin May Improve Survival in Diabetic Men with Prostate Cancer
Avodart Reduces Risk of Biopsy-detected Prostate Cancer
ASTRO and AUA Issue Joint Guideline for Radiation After Prostate Surgery
Genomic Test May Help Guide Prostate Cancer Treatment
Early Radiation Improves Prostate Cancer Survival
Surgery and Radiation for Prostate Cancer Produce Similar Functional Outcomes
Prostate Cancer Screening Can Take a Toll on Quality of Life
New biopsy method shows prostate cancers considered ‘low risk’ may be anything but
Intermittent and Continuous Hormone Therapy are Equally Effective in Prostate Cancer Treatment
Men with a Multidisciplinary Treatment Team Tend to Choose Active Surveillance in the Face of Prostate Cancer.
Surgery and Active Surveillance Produce Equivalent Outcomes in Early Prostate Cancer.
Men with Cardiovascular Disease More Likely to Regret Prostate Cancer Treatment.
Side Effects of Prostate Cancer Treatment Persist Long-Term
Continuous Hormonal Therapy More Effective For Advanced Prostate Cancer.
FDA Adds Warning to Drugs Used in the Treatment of Prostate Cancer
Hemoglobin Decline Linked with Worse Outcomes in Men with Metastatic Prostate Cancer.
Denosumab Improves Bone Density in Prostate Cancer Patients
New Targeted Drug Improves Prostate Cancer Survival.
Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor
Gene Mutation Linked with Increased Risk of Prostate Cancer.
Active Surveillance Linked with Better Quality of Life in Prostate Cancer.
Cabozantinib Active against Advanced Prostate Cancer.
Changes in Lifestyle May Improve Quality of Life for Prostate Cancer Survivors
Addition of Radiation Improves Survival in High-Risk Prostate Cancer.
“Watchful Waiting” in Prostate Cancer Does Not Increase Anxiety.
Androgen Suppression Improves Outcomes in Some Patients with Early Prostate Cancer
Factors Associated with CAM Use By Localized Prostate Cancer Patients
Brothers of Prostate Cancer Patients Undergo More Diagnostic Testing
Additional Evidence That Active Surveillance is an Option for Low-Risk Prostate Cancer.
Drug May Delay Need for Prostate Cancer Treatment.
Jevtana Approved for Hormone-refractory Prostate Cancer
Advanced Treatments Increasingly Used Among Men with a Low Risk of Dying from Prostate Cancer
Hormone Therapy Poses Risks for Prostate Cancer Patients with Heart Problems.
Addition of Hormonal Therapy to Radiation Therapy Benefits Men with Intermediate-Risk Prostate Cancer.
Medicare Will Cover Provenge for Prostate Cancer.
More Men with Low-Risk Prostate Cancer Are Delaying Treatment until Progression
Intermittent Hormone Therapy Effective for Prostate Cancer.
Plenaxis™ Improves Quality of Life for Patients with Advanced Prostate Cancer
Avodart May Slow Prostate Cancer Growth.
Gene-based Test Available to Detect Prostate Cancer
Delayed Surgery for Early Prostate Cancer May Be Safe
Study Evaluates Biochemical Recurrence and Mortality in Men with Prostate Cancer
Death from Other Causes Among Men with Early-stage Prostate Cancer
Dogs May Be Able to Smell Prostate Cancer
External Beam Radiation Raises Risk of Hip Fracture in Prostate Cancer
Addition of Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer
Denosumab More Effective Than Zometa in Prostate Cancer Patients with Bone Metastases
Weight Gain Increases Risk of Prostate Recurrence
Investigational Drug Shows Activity in Advanced Prostate Cancer
Family Intervention Helps Spouses of Prostate Cancer Patients
High-dose Radiation Produces Superior Cancer Control in Localized Prostate Cancer
Provenge® Prolongs Survival in Hormone Refractory Prostate Cancer
Neoadjuvant Chemotherapy for High-risk Localized Prostate Cancer Is Safe and Effective
Addition of Hormone Therapy to Radiation Improves Survival in Intermediate-risk, Early-stage Prostate Cancer
Cabazitaxel Shows Promise in Advanced Prostate Cancer.
Men Who Forgo Aggressive Treatment for Prostate Cancer Don’t Receive Appropriate Monitoring
Good Long-term Results with Intensity Modulated Radiation Therapy for Prostate Cancer.
Denosumab More Effective Than Zometa in Prostate Cancer Patients with Bone Metastases.
Prostatectomy and Radiation More Effective for Locally Advanced Prostate Cancer.
Diagnosis of Prostate Cancer May Improve Overall Health of Some Men
Prostate Cancer and the Increased Risk of Blood Clots
Salvage Radiotherapy Improves Prostate Cancer-specific Survival
Addition of Androgen Deprivation Therapy Improves Survival with Locally Advanced Prostate Cancer.
Hormone Therapy in Prostate Cancer Increases Risk of Heart Disease.
Fluctuation in Weight May Influence Risk for Prostate Cancer
The sexually transmitted infection Trichomonas vaginalis may increase the risk of advanced prostate cancer.
Androgen-deprivation Therapy Increases Risk of Death in Men with Heart Disease.